Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Myokardia Inc (MYOK): Cormorant Asset Management Raises Its Stake

A recent 13G filing with the Securities and Exchange Commission revealed that Bihua Chen‘s Cormorant Asset Management has boosted its stake in Myokardia Inc (NASDAQ:MYOK) to 1.61 million shares, which represent 5.12% of the float. Previously, Cormorant Asset Management’s stake in the company consisted of 758,290 shares, as per its 13F filing for the reporting period of June 30.

Myokardia Inc (NASDAQ:MYOK) is a clinical-stage biopharmaceutical company that works on producing therapeutics for treating a group of rare heart disorders. Over the past 12 months, the company’s stock has gained 51.28%. For the second quarter of 2016, Myokardia disclosed a loss per share of $0.37 and revenue of $3.5 million, compared to a loss per share of $2.78 and the same revenue for the corresponding period of 2015. Recently, Wedbush reiterated its ‘Outperform’ rating on Myokardia’s stock but lowered its price target on it to $22 from $24.



Six of the smart money managers contained in our database reported holding long positions in Myokardia Inc (NASDAQ:MYOK) as of the end of June, down by one from the end of March. Among the bullish investors were Christopher Medlock James’ Partner Fund Management, which held a position valued at $10.40 million, Joseph Edelman’s Perceptive Advisors, with a position worth $6.24 million,  James E. Flynn’s Deerfield Management, and Richard Driehaus’ Driehaus Capital.

Follow Myokardia Inc (NASDAQ:MYOK)
Trade (NASDAQ:MYOK) Now!

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Cormorant Global Healthcare Master Fund 0 1,339,426 0 1,339,426 1,339,426 4.27%
Cormorant Global Healthcare GP 0 1,339,426 0 1,339,426 1,339,426 4.27%
Cormorant Asset Management 0 1,605,790 0 1,605,790 1,605,790 5.12%
Bihua Chen 0 1,605,790 0 1,605,790 1,605,790 5.12%

Bihua Chen
Bihua Chen
Cormorant Asset Management

Page 1 of 8 – SEC Filing

Washington, D.C. 20549
Under the Securities Exchange Act of 1934
(Amendment No. ___)*
Myokardia, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
(CUSIP Number)
September 28, 2016
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ]            Rule 13d-1(b)
[x]            Rule 13d-1(c)
[ ]            Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.